Zacks Research Upgrades Assembly Biosciences (NASDAQ:ASMB) to “Strong-Buy”

Assembly Biosciences (NASDAQ:ASMB) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

A number of other analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research report on Tuesday. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Guggenheim reissued a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Assembly Biosciences has an average rating of “Moderate Buy” and an average price target of $44.00.

Assembly Biosciences Stock Performance

Shares of NASDAQ ASMB opened at $34.38 on Thursday. Assembly Biosciences has a 52-week low of $20.23 and a 52-week high of $39.71. The stock has a market cap of $700.01 million, a P/E ratio of 33.71 and a beta of 1.10. The firm has a 50 day moving average price of $27.11 and a 200 day moving average price of $27.60.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. Analysts predict that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently made changes to their positions in ASMB. Acadian Asset Management LLC raised its holdings in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares during the period. Geode Capital Management LLC boosted its stake in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 3,312 shares during the period. Vanguard Group Inc. increased its holdings in Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Assembly Biosciences during the 3rd quarter worth about $485,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Assembly Biosciences in the 3rd quarter valued at about $3,120,000. Institutional investors own 19.92% of the company’s stock.

Key Assembly Biosciences News

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and maintained a “Buy” rating with a $50 price target, signaling improved expectations for the company’s near-term earnings. HC Wainwright Assembly Biosciences estimates
• Positive Sentiment: The analyst also raised estimates for several periods, including Q3 2026 EPS to a loss of $0.44 from a loss of $0.69, Q1 2027 EPS to positive $0.02 from a loss of $0.16, and FY2027 EPS to a loss of $0.02 from a loss of $0.77. These revisions suggest expectations for a substantially better earnings trajectory.
• Positive Sentiment: Assembly Biosciences was added to Zacks’ Rank #1 (Strong Buy) list and its momentum-focused Strong Buy list. Such rankings may attract momentum-oriented investors, although they are based largely on quantitative factors. Zacks momentum stocks
• Positive Sentiment: Analysts continue to show constructive sentiment: HC Wainwright reiterated its “Buy” rating, while the broader analyst consensus was reported as “Moderate Buy.” Another Zacks analysis cited average analyst price targets implying significant potential upside, while cautioning that price targets are an imperfect forecasting tool. HC Wainwright Buy rating
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69, partially offsetting the broader upward revisions. The company remains dependent on future earnings improvements, and analyst forecasts for some 2027 quarters still call for losses.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.